1. Home
  2. IGIC vs ATAI Comparison

IGIC vs ATAI Comparison

Compare IGIC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International General Insurance Holdings Ltd.

IGIC

International General Insurance Holdings Ltd.

HOLD

Current Price

$24.99

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

ATAI

ATAI Life Sciences N.V.

HOLD

Current Price

$4.22

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IGIC
ATAI
Founded
2001
2018
Country
Jordan
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2019
2025

Fundamental Metrics

Financial Performance
Metric
IGIC
ATAI
Price
$24.99
$4.22
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$28.00
$15.88
AVG Volume (30 Days)
32.3K
6.6M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
5.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,089,000.00
Revenue This Year
$0.13
N/A
Revenue Next Year
$2.54
N/A
P/E Ratio
$9.05
N/A
Revenue Growth
N/A
1227.60
52 Week Low
$20.82
$1.29
52 Week High
$27.43
$6.73

Technical Indicators

Market Signals
Indicator
IGIC
ATAI
Relative Strength Index (RSI) 41.49 53.07
Support Level $24.70 $4.05
Resistance Level $25.55 $4.30
Average True Range (ATR) 0.78 0.34
MACD -0.23 -0.04
Stochastic Oscillator 0.20 22.42

Price Performance

Historical Comparison
IGIC
ATAI

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.

About ATAI ATAI Life Sciences N.V.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Share on Social Networks: